For example, Berzosertib is a highly potent and first-in-class ATR inhibitor that has demonstrated promising results during phases I and/or II clinical trials against non-small cell lung cancer (NSCLC) [13], small cell lung cancer [14], triple-negative breast cancer [15], high-grade serous ovarian cancer [16], and advanced solid tumors [17, 18]. This evidence concerns the gene ATR and non-small cell lung carcinoma.